---
title: "Neurotech International Enhances Cannabinoid Drug Development Through New Partnership"
date: "2025-02-13 08:38:29"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioAn announcement from Neurotech International Ltd...."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1264051801-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

An announcement from Neurotech International Ltd. ( [(AU:NTI)](https://www.tipranks.com/stocks/au:nti) ) is now available.

Neurotech International Ltd has entered into a development agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company, to create a pharmaceutical-grade broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders. This collaboration is intended to expand Neurotech’s market reach and enhance product quality using ECC’s expertise in cannabis-based product development and manufacturing. The agreement aligns with Neurotech’s strategic goal to meet global demand for high-quality cannabis-derived pharmaceuticals and further reinforces the company’s position in the industry.

**More about Neurotech International Ltd.**

Neurotech International Limited is a clinical-stage biopharmaceutical development company focused primarily on pediatric neurological disorders. The company offers a broad-spectrum oral cannabinoid drug therapy, NTI164, and has conducted various clinical trials in Autism Spectrum Disorder (ASD) and other pediatric neuropsychiatric disorders. Neurotech is committed to innovation and regulatory compliance, with ongoing efforts in clinical trials and collaborations with medical institutions.

**YTD Price Performance:** -26.67%

**Average Trading Volume:** 655,913

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** A$45.85M

See more data about NTI stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/au:nti/stock-analysis).

Trending Articles:
------------------

* [FCC Takes Aim at Comcast (NASDAQ:CMCSA) Over DEI Policies](https://www.tipranks.com/news/fcc-takes-aim-at-comcast-nasdaqcmcsa-over-dei-policies)
* [Trump Policies May Mean Layoffs at Ford (NYSE:F)](https://www.tipranks.com/news/trump-policies-may-mean-layoffs-at-ford-nysef)
* [A New Joint Venture For Intel (NASDAQ:INTC)?](https://www.tipranks.com/news/a-new-joint-venture-for-intel-nasdaqintc)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/neurotech-international-enhances-cannabinoid-drug-development-through-new-partnership)
